Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.
Shares of Quest Diagnostics Inc. DGX slid 1.10% to $178.28 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.23% to ...
Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in ...
Zacks Investment Research on MSN
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
A merger would significantly change the competitive scene. With Quest and Labcorp being major players, their combination ...
Europe: Labcorp recently took a stake in SYNLAB, a big European lab company. This could be a way to test the waters and see ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback